CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)


Free download. Book file PDF easily for everyone and every device. You can download and read online CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) book. Happy reading CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) Bookeveryone. Download file Free Book PDF CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) Pocket Guide.
Description

It has been suggested that both the lack of alkaline phosphatases in the endothelium and the acidic conditions in the microenvironment prevent the activation of amifostine in the tumor, assuring a selective protection of normal tissues. Conversely, there is clinical evidence to support the use of amifostine. No difference after 2 years was observed in locoregional control or survival.


  • 16.1 INTRODUCTION.
  • Proceedings of the Conference on Banach Algebras and Several Complex Variables.
  • Surface Diffusion: Atomistic and Collective Processes.

To date, however, no trial has been powered sufficiently to detect small differences in survival. Another important issue is the toxicity of amifostine. Nausea and emesis are common side effects, but they generally are mild and can be controlled effectively with standard antiemetic medication. There is a risk of transient hypotension when amifostine is administered intravenously administered, but not when it is administered subcutaneously.

See a Problem?

The extent of the damage caused by RT depends both on the volume of tissue that is irradiated and on the dose of radiation that is delivered. A high dose is administered to a small part of the parotid and is positioned close to the tumor, while the rest of the gland receives a low dose or no dose at all. Patients who received that treatment have gained partial sparing of the salivary output from the parotid gland.

There also is evidence that reduction of xerostomia results in improved QoL. Lin and colleagues reported that both xerostomia and QoL scores improved significantly over time during the first year after IMRT. Data regarding the doses and irradiated volumes that permit preservation of the salivary flow after RT are emerging slowly. Usually, 3D dose distributions in parotid glands are compared with residual saliva production. It became clear that there is an exponential relation between saliva flow reduction and mean parotid dose for each gland, suggesting that it is essential to respect a certain threshold for mean parotid dose to preserve gland function.

However, the use of a mean dose as a threshold for the control of normal tissue tolerance is helpful only when an organ consists of independent functional units that are organized in parallel.

Radiation Therapy for Prostate Cancer

In such an organ, irradiation of a small part results in less loss of function than in an organ that has a serial anatomic organization. In the latter case, damage to 1 substructure disables the entire organ eg, the spinal cord.

Medical School

For the healthy parotid gland, it is generally assumed that a homogenous distribution of saliva production takes place over the entire volume. It was suggested that spatial information should be included in the comparison of different plans and that the mean dose concept has limited use for the prediction of late radiation damage. Similarly, it remains to be determined whether regional differences in gland radiosensitivity will prove to be equally important in humans as they appear to be in rats.

Before RT, all slices contributed equally; 7 months after an average dose of There was high interpatient variability in D50, and low doses 10—15 Gy also could induce serious loss of function, casting doubt on the utility of a general, standard, mean gland dose threshold. Probably, the mean parotid dose should be kept as low as possible. Colleagues Jha et al and Seikaly et al were the first to propose surgical transfer of 1 submandibular gland to the submental space, outside the proposed radiation field. Obviously, it is not always straightforward to predict which patients will need postoperative RT, and some patients may refuse further treatment.

Then again, in some patients, the submental space cannot be shielded because of its proximity to the disease.

These are important limitations, and, in the largest study to date, 17 of 60 patients However, all of the glands survived transfer and functioned well; the surgical technique had no complications and added an average of 45 minutes to the surgical protocol. A variety of artificial saliva substitutes have been developed to supplement the reduced production of saliva, although very few have been evaluated appropriately. Obviously, because saliva is a complex substance with many functions, it is difficult to replace; therefore, saliva substitutes rarely are effective, and some patients find regular sips of water equally useful.

Antimicrobial mouthwashes, such as chlorhexidine and hexitidine, play a central role in reducing the bacterial load and inhibiting cariogenesis. Studies have shown that, when there still is some residual salivary function, saliva stimulants produce greater relief than saliva substitutes. Pilocarpine obviously is contraindicated in patients who have asthma, acute iritis, or glaucoma and should be used with extreme caution in patients who have chronic obstructive pulmonary disease and cardiovascular disease.

Some work has been done with topical ie, oral application of pilocarpine, which seemed to produce results similar to those achieved with systemic delivery methods but with improved patient tolerance. Some promising preclinical results have been obtained by gene transfer, although clinical studies have yet to be initiated. Apparently, mobilized bone marrow cells may home to salivary glands and induce repair by secreting stimulatory factors, causing improved salivary gland function.

Therefore, further research, particularly regarding treatment, is urgently warranted. Volume , Issue The full text of this article hosted at iucr. Get A Copy. Hardcover , pages. More Details Original Title. Other Editions 3. Friend Reviews. To see what your friends thought of this book, please sign up. To ask other readers questions about Cured I - Lent , please sign up.

Lists with This Book. This book is not yet featured on Listopia. Community Reviews. Showing Rating details. All Languages.

Cured I - Lent: Late Effects of Cancer Treatment on Normal Tissues by Philip Rubin

More filters. Effects of gamma-irradiation on the M-CSF-promoter linked to a chloramphenicol aminoacyl transferase reporter gene expressed in a clonal murine bone marrow stromal cell line. Stem Cells. Primary radiation therapy for endometrial carcinoma: a case controlled study. Tolerances in setup and dosimetric errors in the radiation treatment of breast cancer. The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-src.

Radiat Res. Humoral and cell surface interactions during gamma-irradiation leukemogenesis in vitro. Exp Hematol. Electron beam modifications for the treatment of superficial malignancies. The v-abl, c-fms, or v-myc oncogene induces gamma radiation resistance of hematopoietic progenitor cell line 32d cl 3 at clinical low dose rate. Study of dose perturbation parameters for eye shielding in megavoltage photon beam therapy. Hematopoietic stem cell- and marrow stromal cell-specific requirements for gamma irradiation leukemogenesis in vitro.

Gamma-irradiation response of cocultivated bone marrow stromal cell lines of differing intrinsic radiosensitivity.


  1. Radiation Therapy for Prostate Cancer.
  2. Macroeconomics for MBAs and Masters of Finance.
  3. CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues / Edition 1.
  4. Aesthetic results following partial mastectomy and radiation therapy. Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum CDDP and i. A phase II trial. Am J Clin Oncol. Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate.

    Resistance of hematopoietic stem cells to x-irradiation at clinical low-dose rate is induced by several classes of oncogenes. Rad Res Recent Studies of the hematopoietic microenvironment in long-term bone marrow cultures. Immunol Res. Recombinant murine GM-CSF increases resistance of some factor dependent hematopoietic progenitor cells to low-dose-rate gamma radiation. Increase in low-dose rate x-irradiation resistance of factor dependent hematopoietic progenitor cells by recombinant murine GM-CSF.

    Long-term bone marrow cultures: recent studies with clonal hematopoietic and stromal cell lines. Pathol Immunopathol Res 8 1 Retroviral src gene expression in continuous marrow culture increases the self-renewal capacity of multilineage hematopoietic stem cells. Leukemia Radiosensitivity of human prostate cancer and malignant melanoma cell lines. Radiother Oncol. Bitran JD, et al, Eds. Orlando, FL Grune and Stratton, pp. Radiosensitivity of cloned permanent murine bone marrow stromal cell lines: Non-uniform effect of low dose rate.

    Exp Hematol Radiosensitivity of permanent human bone marrow stromal cell lines: Effect of dose rate.

    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)
    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)
    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)
    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)
    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)
    CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology) CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)

Related CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues (Medical Radiology)



Copyright 2019 - All Right Reserved